Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | NPY2R | P49146 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20605293 | 0.84 | ALDH1A1 (0.40) | IMPDH2ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL20605289 | 0.84 | ALDH1A1 (0.40) | IMPDH2ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL19322331 | 0.78 | ALDH1A1 (0.38) | IMPDH2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2249224 | 0.77 | ALDH1A1 (0.37) | ALDH1A1LMNAMEN1HTTKMT2A | |
| SCHEMBL24167727 | 0.77 | EGFR (0.40) | IMPDH2ALDH1A1LMNAMEN1HTT | |
| SCHEMBL6588041 | 0.77 | EGFR (0.40) | IMPDH2ALDH1A1LMNAMEN1HTT | |
| SCHEMBL6584471 | 0.77 | EGFR (0.40) | IMPDH2ALDH1A1LMNAMEN1HTT | |
| SCHEMBL30478652 | 0.77 | ALDH1A1 (0.35) | IMPDH2ALDH1A1NPY2RMAPTGAA | |
| SCHEMBL19322333 | 0.76 | ALDH1A1 (0.41) | IMPDH2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL22076876 | 0.74 | NPC1 (0.37) | ALDH1A1LMNAMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| US-8003658-B2 | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-23 | — | — | US | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | IMPDH2 1736/4885ALDH1A1 2222/4885NPY2R 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.